Research analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR – Get Free Report) in a research report issued on Monday. The brokerage set a “sell” rating on the stock.
Separately, Piper Sandler restated an “overweight” rating and issued a $4.50 price objective on shares of InspireMD in a research report on Tuesday, September 17th.
Read Our Latest Report on NSPR
InspireMD Price Performance
InspireMD (NYSE:NSPR – Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The business had revenue of $1.74 million for the quarter, compared to analysts’ expectations of $1.74 million. InspireMD had a negative return on equity of 62.02% and a negative net margin of 388.67%. During the same quarter in the previous year, the firm earned ($0.24) earnings per share. On average, analysts expect that InspireMD will post -0.82 earnings per share for the current year.
Institutional Investors Weigh In On InspireMD
An institutional investor recently bought a new position in InspireMD stock. Mesirow Financial Investment Management Inc. acquired a new stake in InspireMD, Inc. (NYSE:NSPR – Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 30,000 shares of the company’s stock, valued at approximately $71,000. Mesirow Financial Investment Management Inc. owned approximately 0.13% of InspireMD as of its most recent filing with the SEC. Institutional investors own 44.78% of the company’s stock.
InspireMD Company Profile
InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.
See Also
- Five stocks we like better than InspireMD
- Upcoming IPO Stock Lockup Period, Explained
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Basic Materials Stocks Investing
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- How to Use the MarketBeat Stock Screener
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.